Markets:

Overview

News

Currencies

International

Treasuries

Natera, Inc. - Common Stock (NQ:NTRA)

197.37 +4.83 (+2.51%)

Streaming Delayed Price Updated: 3:48 PM EDT, May 19, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Natera, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

20 21 Next >

1 Mid-Cap Stock with Exciting Potential and 2 That Underwhelm

Today 0:39 EDT

Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. Howe...

Via StockStory

5 Must-Read Analyst Questions From Natera’s Q1 Earnings Call

May 14, 2026

Natera’s first quarter was marked by robust top-line growth and higher-than-expected sales volumes, but the market responded negatively due to a wider-than-a...

Via StockStory

Topics Earnings

Why Natera (NTRA) Shares Are Plunging Today

May 08, 2026

What Happened? Shares of genetic testing company Natera (NASDAQ:NTRA). fell 12.2% in the afternoon session after the company reported mixed first-quarter 202...

Via StockStory

Topics Artificial Intelligence Economy

Natera Q1 Earnings Call Highlights ↗

May 08, 2026

Natera (NASDAQ:NTRA) reported first-quarter 2026 revenue of $697 million, up 39% year over year, as the company delivered more than 1 million total units in a single quarter for the first time. Chief...

Via MarketBeat

Topics Earnings

Natera (NTRA) Q1 Revenue Beat Overshadowed by EPS Miss and Operating Losses ↗

May 07, 2026

Via Chartmill

NTRA Q1 Deep Dive: Robust Volume Growth and Product Expansion Shape Outlook

May 08, 2026

Genetic testing company Natera (NASDAQ:NTRA). reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 38.8% year on year to $696....

Via StockStory

Natera NTRA Q1 2026 Earnings Call Transcript ↗

May 07, 2026

Natera NTRA Q1 2026 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Natera’s (NASDAQ:NTRA) Q1 CY2026 Sales Top Estimates

May 07, 2026

Genetic testing company Natera (NASDAQ:NTRA). announced better-than-expected revenue in Q1 CY2026, with sales up 38.8% year on year to $696.6 million. Its GA...

Via StockStory

Natera Reports First Quarter 2026 Financial Results

May 07, 2026

From Natera, Inc.

Via Business Wire

What To Expect From Natera’s (NTRA) Q4 Earnings

May 05, 2026

Genetic testing company Natera (NASDAQ:NTRA). will be announcing earnings results this Thursday afternoon. Here’s what to expect. Natera beat analysts’ reven...

Via StockStory

Natera to Report its First Quarter Results on May 7, 2026

April 30, 2026

From Natera, Inc.

Via Business Wire

Prospera™ Evidence in Heart and Lung Transplantation Featured Across 17 Presentations at ISHLT

April 22, 2026

From Natera, Inc.

Via Business Wire

Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)

April 20, 2026

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...

Via StockStory

Topics Artificial Intelligence

3 Reasons We’re Fans of Natera (NTRA)

April 20, 2026

Natera has had an impressive run over the past six months as its shares have beaten the S&P 500 by 6%. The stock now trades at $208.20, marking a 10.5% gain....

Via StockStory

Topics Stocks

Natera, UFP Technologies, Mettler-Toledo, and Viatris Shares Are Soaring, What You Need To Know

April 17, 2026

What Happened? A number of stocks jumped in the afternoon session after the reopening of the Strait of Hormuz signaled a cooling of global logistics and ener...

Via StockStory

Topics Economy Government Stocks

1 Cash-Producing Stock to Own for Decades and 2 That Underwhelm

April 15, 2026

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...

Via StockStory

Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics’ MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma

April 13, 2026

From Natera, Inc.

Via Business Wire

Judge Awards 30% Ongoing Royalty to Natera for its MRD-Related Patents

April 09, 2026

From Natera, Inc.

Via Business Wire

1 of Wall Street’s Favorite Stock with Exciting Potential and 2 We Find Risky

April 09, 2026

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f...

Via StockStory

3 Reasons NTRA Has Explosive Upside Potential

April 09, 2026

Even during a down period for the markets, Natera has gone against the grain, climbing to $211.23. Its shares have yielded a 22.1% return over the last six m...

Via StockStory

20 Abstracts at AACR Highlight Scale, Innovation and Clinical Impact of Natera’s Oncology Platform

April 07, 2026

From Natera, Inc.

Via Business Wire

SignateraTM MRD Identifies Breast Cancer Patients Who Can Forgo Surgery

March 31, 2026

From Natera, Inc.

Via Business Wire

Elanco, Tandem Diabetes, Fortrea, Natera, and Myriad Genetics Shares Plummet, What You Need To Know

March 27, 2026

What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as in...

Via StockStory

Topics Government Stocks

Abbott Laboratories Finalizes $21 Billion Acquisition of Exact Sciences, Redefining the Future of Cancer Diagnostics

March 23, 2026

CHICAGO — In a move that fundamentally reshapes the global diagnostics landscape, Abbott Laboratories (NYSE: ABT) officially completed its $21 billion acquisition of Exact Sciences (NASDAQ: EXAS)...

Via MarketMinute

Topics Supply Chain

1 Unprofitable Stock to Own for Decades and 2 Facing Headwinds

March 20, 2026

Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, th...

Via StockStory

1 Cash-Heavy Stock to Target This Week and 2 We Question

March 19, 2026

A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face c...

Via StockStory

NeoGenomics, Natera, and Amphastar Pharmaceuticals Shares Skyrocket, What You Need To Know

March 16, 2026

What Happened? A number of stocks jumped in the afternoon session after easing crude oil prices helped lift investor sentiment and reduce inflation worries. ...

Via StockStory

Topics Economy Stocks

This Biotech Stock Surged 75% Last Quarter and Pulled a New $9 Million Investment ↗

March 16, 2026

Vera Therapeutics develops clinical-stage therapies for serious immunological diseases, with a lead candidate targeting kidney disorders.

Via The Motley Fool

Topics Regulatory Compliance

This Life Sciences Supplier Has Plunged 50% in a Year, but One Fund Bought Up $28 Million More in Stock ↗

March 16, 2026

Avantor delivers laboratory materials and specialized services to biopharma, healthcare, and advanced technology clients worldwide.

Via The Motley Fool

Topics Regulatory Compliance Supply Chain

Two Publications Highlight Clinical Utility of Signatera™ in Anal and Rectal Cancers

March 16, 2026

From Natera, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

20 21 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Natera, Inc. - Common Stock (NQ:NTRA)

All News about Natera, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today